{"id":26004,"date":"2021-04-13T10:31:14","date_gmt":"2021-04-13T08:31:14","guid":{"rendered":"https:\/\/www.apiagentura.gov.cz\/?p=26004"},"modified":"2021-04-15T09:17:56","modified_gmt":"2021-04-15T07:17:56","slug":"uspesne-projekty-op-pik-vidia-rozsireni-vyrobniho-programu-spolecnosti","status":"publish","type":"post","link":"https:\/\/apiagentura.gov.cz\/cs\/uspesne-projekty-op-pik-vidia-rozsireni-vyrobniho-programu-spolecnosti\/","title":{"rendered":"\u00dasp\u011b\u0161n\u00e9 projekty OP PIK: VIDIA \u2013 roz\u0161\u00ed\u0159en\u00ed v\u00fdrobn\u00edho programu spole\u010dnosti"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n

PROFIL SPOLE\u010cNOSTI<\/strong><\/p>\n

Firma VIDIA spol. s r.o. je soukrom\u00e1 \u010desk\u00e1 biotechnologick\u00e1 firma, kter\u00e1 se ji\u017e 30 let zab\u00fdv\u00e1 v\u00fdvojem, v\u00fdrobou a distribuc\u00ed diagnostick\u00fdch souprav pro hum\u00e1nn\u00ed medic\u00ednu a \u017eivotn\u00ed prost\u0159ed\u00ed. Byla zalo\u017eena v roce 1991 v\u011bdecko-v\u00fdzkumn\u00fdmi pracovn\u00edky v \u010dele s\u00a0virologem RNDr. Jaroslavem Roubalem, CSc. D\u00edky dlouholet\u00fdm zku\u0161enostem ve zdravotnick\u00e9 v\u00fdrob\u011b, profesion\u00e1ln\u00edmu t\u00fdmu, modern\u00edmu vybaven\u00ed laborato\u0159\u00ed \u00fasp\u011b\u0161n\u011b realizuje v\u0161echny stupn\u011b procesu v\u00fdroby VIDITEST souprav, od p\u0159\u00edpravy jednotliv\u00fdch komponent a\u017e po v\u00fdstupn\u00ed kontrolu. VIDIA dod\u00e1v\u00e1 sv\u00e9 v\u00fdrobky do v\u00edce ne\u017e 20 zem\u00ed Evropy, Ameriky a Asie.<\/p>\n

POPIS PROJEKTU<\/strong><\/p>\n

Spole\u010dnost VIDIA vyu\u017eila dotaci na roz\u0161\u00ed\u0159en\u00ed v\u00fdrobn\u00edho programu spole\u010dnosti. Firma \u010derpala finan\u010dn\u00ed podporu z programu Inovace v Opera\u010dn\u00edm programu Podnik\u00e1n\u00ed a inovace pro konkurenceschopnost (OP PIK).<\/p>\n

Projekt se zam\u011b\u0159il na zaveden\u00ed inovace produkt\u016f a technologie v\u00fdroby multiplex\u016f<\/strong> \u2013 prou\u017ekov\u00fdch membr\u00e1nov\u00fdch test\u016f pro pou\u017eit\u00ed p\u0159i diagnostice nej\u010dast\u011bj\u0161\u00edch p\u016fvodc\u016f infekc\u00ed p\u0159en\u00e1\u0161en\u00fdch kl\u00ed\u0161\u0165aty a nej\u010dast\u011bj\u0161\u00edch p\u016fvodc\u016f neuroinfekc\u00ed a VIDIA Elisa test\u016f ve form\u00e1tu kazetov\u00e9ho syst\u00e9mu<\/strong> pro pou\u017eit\u00ed v automatick\u00fdch analyz\u00e1torech ve zdravotnick\u00fdch laborato\u0159\u00edch. Oba druhy test\u016f vze\u0161ly z vlastn\u00edho v\u00fdvoje. Sou\u010d\u00e1st\u00ed projektu byla tak\u00e9 organiza\u010dn\u00ed inovace spo\u010d\u00edvaj\u00edc\u00ed v po\u0159\u00edzen\u00ed software na \u0159\u00edzen\u00ed v\u00fdroby a skladov\u00e1n\u00ed s\u00a0p\u0159\u00edslu\u0161enstv\u00edm. D\u00edky proveden\u00fdm inovac\u00edm m\u016f\u017ee nyn\u00ed VIDIA nab\u00eddnout laborato\u0159\u00edm, kter\u00e9 jsou jej\u00edmi koncov\u00fdmi z\u00e1kazn\u00edky, kvalitn\u00ed, p\u0159esn\u00e9 a rychl\u00e9 kombinovateln\u00e9 testy p\u0159in\u00e1\u0161ej\u00edc\u00ed zefektivn\u011bn\u00ed pr\u00e1ce v laborato\u0159i a \u00fasporu materi\u00e1lu.<\/p>\n

Multiplexy<\/strong><\/p>\n

Diagnostick\u00e9 a analytick\u00e9 laborato\u0159e mnoha odv\u011btv\u00ed \u010del\u00ed v sou\u010dasn\u00e9 dob\u011b st\u00e1le v\u011bt\u0161\u00edm po\u017eadavk\u016fm na rychl\u00e9 a komplexn\u00ed vy\u0161et\u0159en\u00ed poskytuj\u00edc\u00ed najednou v\u00edce informac\u00ed. Proto se trend sou\u010dasn\u00e9 diagnostiky ub\u00edr\u00e1 sm\u011brem k vyu\u017e\u00edv\u00e1n\u00ed multiplexov\u00fdch metod, kter\u00e9 umo\u017e\u0148uj\u00ed z\u00edskat z jednoho testu v\u00edce po\u017eadovan\u00fdch v\u00fdsledk\u016f, co\u017e vede k rychlej\u0161\u00edmu v\u00fdsledku a \u00faspor\u00e1m v materi\u00e1ln\u00edch a person\u00e1ln\u00edch n\u00e1kladech zdravotnick\u00e9ho za\u0159\u00edzen\u00ed. V r\u00e1mci v\u00fdvoje se spole\u010dnosti VIDIA poda\u0159ilo p\u0159ipravit Multiplex testy zalo\u017een\u00e9 na LIA (imuno-line assay) technologii pro diagnostiku neuroinfekc\u00ed a panelu TORCH (Toxo, Rubella, CMV, HSV1,2). Na trhu dosud neexistuj\u00ed multiplex LIA testy na neuroinfekce, existuj\u00edc\u00ed testy pro panel TORCH obsahuj\u00ed odli\u0161n\u00e9 formy a po\u010dty antigen\u016f.<\/p>\n

Kazety<\/strong><\/p>\n

V sou\u010dasn\u00e9 dob\u011b lze v automatick\u00fdch analyz\u00e1torech ve zdravotnick\u00fdch laborato\u0159\u00edch prov\u00e1d\u011bt bu\u010f v\u011bt\u0161\u00ed mno\u017estv\u00ed test\u016f jednoho typu (ELISA automat), nebo jednotliv\u00e9 testy (kazetov\u00fd syst\u00e9m, obvykle funguj\u00edc\u00ed na principu chemiluminiscence nebo ELISA). Syst\u00e9m, kter\u00fd by kombinoval ob\u011b mo\u017enosti v jednom p\u0159\u00edstroji, nen\u00ed v Evrop\u011b zn\u00e1m\u00fd. VIDIA vyvinula princip, jak ELISA testy pou\u017eiteln\u00e9 v ru\u010dn\u00edm proveden\u00ed i v\u00a0proveden\u00ed na automatick\u00fdch analyz\u00e1torech, transformovat do kazet. \u0158e\u0161en\u00ed umo\u017en\u00ed men\u0161\u00edm laborato\u0159\u00edm zv\u00fd\u0161it p\u0159esnost a standardnost test\u016f, pou\u017e\u00edvat kvalitn\u011bj\u0161\u00ed testy a l\u00e9pe hospoda\u0159it s materi\u00e1lem.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n

\"\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n

\"\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n

Jak\u00e9 v\u00fdsledky realizace projektu p\u0159inesla, na to n\u00e1m odpov\u00eddala:<\/strong><\/p>\n

Ing. Michaela Pol\u00e1kov\u00e1, jednatelka a mana\u017eerka kvality spole\u010dnosti Vidia<\/p>\n

Co projekt va\u0161\u00ed firm\u011b p\u0159inesl? <\/strong><\/p>\n

Projekt n\u00e1m p\u0159inesl p\u0159edev\u0161\u00edm mo\u017enost optimalizovat a zefektivnit vlastn\u00ed proces v\u00fdroby n\u00e1mi vyvinut\u00fdch produkt\u016f. Bez t\u00e9to podpory by nebylo mo\u017en\u00e9 nav\u00fd\u0161it kapacitu nov\u011b vyr\u00e1b\u011bn\u00fdch test\u016f a z\u00e1rove\u0148 zachovat nebo d\u00e1le vylep\u0161it jejich kvalitu.<\/p>\n

Jak\u00e9 konkr\u00e9tn\u00ed \u00fasp\u011bchy jste u\u017e s\u00a0inovovanou diagnostikou a roz\u0161\u00ed\u0159enou v\u00fdrobou zaznamenali? <\/strong><\/p>\n

Vyu\u017eit\u00ed bohu\u017eel v\u00a0sou\u010dasn\u00e9 dob\u011b dost ovlivnil nouzov\u00fd stav, kdy se lid\u00e9 ob\u00e1vaj\u00ed chodit k\u00a0l\u00e9ka\u0159\u016fm i se z\u00e1va\u017en\u00fdmi diagn\u00f3zami jako jsou boreli\u00f3za a encefalitida. Nicm\u00e9n\u011b i tak jsme ji\u017e na trh uvedli mno\u017estv\u00ed test\u016f, p\u0159edev\u0161\u00edm kazetov\u00fdch, vyroben\u00fdch pomoc\u00ed inovovan\u00fdch postup\u016f.<\/p>\n

Co znamen\u00e1 va\u0161e inovace celkov\u011b pro diagnostiku? P\u0159in\u00e1\u0161\u00ed pacient\u016fm a l\u00e9ka\u0159\u016fm n\u011bjak\u00e9 v\u00fdhody? <\/strong><\/p>\n

Inovace p\u0159in\u00e1\u0161\u00ed v\u00fdhody pro praktick\u00e9 vyu\u017eit\u00ed v\u00a0diagnostick\u00e9 laborato\u0159i \u2013 n\u00e1mi vyv\u00edjen\u00e9 kazetov\u00e9 testy jsou toti\u017e v\u00a0automatu kombinovateln\u00e9 s\u00a0b\u011b\u017en\u00fdmi ELISA testy. Laborato\u0159e maj\u00ed tedy mo\u017enost doplnit standardn\u00ed rutinn\u00ed testy, kter\u00e9 se prov\u00e1d\u011bj\u00ed v\u00a0automatu ve v\u011bt\u0161\u00edm mno\u017estv\u00ed, n\u011bkolika vzorky m\u00e9n\u011b b\u011b\u017en\u00fdch test\u016f. Mal\u00e9 laborato\u0159e zas mohou vyu\u017e\u00edt automat pro otestov\u00e1n\u00ed men\u0161\u00edho po\u010dtu pacientsk\u00fdch vzork\u016f na v\u00edce diagnostick\u00fdch marker\u016f v\u00a0jednom b\u011bhu. V\u00a0obou p\u0159\u00edpadech to umo\u017e\u0148uje vyu\u017e\u00edvat automatizaci na rutinn\u00ed testy, co\u017e je v\u011bt\u0161inou ekonomi\u010dt\u011bj\u0161\u00ed a z\u00e1rove\u0148 se uvoln\u00ed ruce pro dal\u0161\u00ed \u010dinnosti, na kter\u00e9 obvykle nezb\u00fdv\u00e1 \u010das.<\/p>\n

Z jak\u00fdch v\u011bc\u00ed, kter\u00e9 se v\u00e1m d\u00edky dotaci poda\u0159ilo realizovat, m\u00e1te nejv\u011bt\u0161\u00ed radost? <\/strong><\/p>\n

Z\u00a0rychlej\u0161\u00ed a robustn\u011bj\u0161\u00ed pr\u00e1ce, a to p\u0159edev\u0161\u00edm u kazetov\u00fdch test\u016f. Ze za\u010d\u00e1tku jsme v\u0161e d\u011blali ru\u010dn\u011b, vid\u011bt pak automatickou linku v\u00a0provozu je z\u00e1\u017eitek.<\/p>\n

Jak\u00e9 zku\u0161enosti si z realizace projektu odn\u00e1\u0161\u00edte? <\/strong><\/p>\n

Veskrze pozitivn\u00ed, i p\u0159es mno\u017estv\u00ed zm\u011bn v\u00a0projektu v\u0161e b\u011b\u017eelo maxim\u00e1ln\u011b efektivn\u011b.<\/p>\n

Jak\u00fdm partnerem pro v\u00e1s byla Agentura pro podnik\u00e1n\u00ed a inovace (API) a \u0159\u00edd\u00edc\u00ed org\u00e1n Ministerstvo pr\u016fmyslu a obchodu \u010cR (MPO)? <\/strong><\/p>\n

API i MPO byli p\u0159i projektu n\u00e1pomocn\u00ed, komunikace s\u00a0nimi byla p\u0159\u00ednosem p\u0159i p\u0159\u00edprav\u011b i \u0159\u00edzen\u00ed projektu.<\/p>\n

Jak je pro rozvoj va\u0161\u00ed spole\u010dnosti d\u016fle\u017eit\u00e1 spolupr\u00e1ce s v\u00fdzkumn\u00fdmi organizacemi? <\/strong><\/p>\n

Spole\u010dnost up\u0159ednost\u0148uje vlastn\u00ed v\u00fdzkum, nicm\u00e9n\u011b tvo\u0159iv\u00e9 spolupr\u00e1ci se nebr\u00e1n\u00edme. Ob\u010das s\u00a0v\u00fdzkumn\u00fdmi institucemi spolupracujeme tak\u00e9 na nov\u00fdch projektech, \u010dasto ale nar\u00e1\u017e\u00edme na rozd\u00edln\u00fd pohled v\u00fdzkumn\u00e9 a realiza\u010dn\u00ed sf\u00e9ry na to, co je hotov\u00fd v\u00fdsledek.<\/p>\n

Je n\u011bjak\u00e1 zaj\u00edmavost, kterou byste cht\u011bla k\u00a0projektu doplnit? <\/strong><\/p>\n

Jen to, \u017ee p\u0159\u00ednosy projekt\u016f, p\u0159edev\u0161\u00edm pak v\u00fdvoje a zaveden\u00ed nov\u00fdch nebo inovovan\u00fdch produkt\u016f, se obvykle projev\u00ed a\u017e po del\u0161\u00edm \u010dase, dokonce \u010dasto a\u017e po ukon\u010den\u00ed monitorovac\u00edho obdob\u00ed. Z\u00e1rove\u0148 ale n\u00e1klady na jejich uveden\u00ed do provozu a na trh jsou vysok\u00e9. Proto je mo\u017enost z\u00edsk\u00e1n\u00ed dotace velkou pomoc\u00ed, zvl\u00e1\u0161\u0165 pro men\u0161\u00ed rodinn\u00e9 spole\u010dnosti, jako je ta na\u0161e. Bylo by ale p\u0159\u00ednosn\u00e9, kdyby byla mo\u017en\u00e9 z\u00edskat dotaci p\u0159edem, alespo\u0148 \u010d\u00e1ste\u010dn\u011b, dodate\u010dn\u00e9 financov\u00e1n\u00ed je velkou z\u00e1t\u011b\u017e\u00ed pro cash flow.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n

\"\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n
\n
\n

Z\u00c1KLADN\u00cd INFORMACE O PROJEKTU<\/strong><\/p>\n

\u00a0<\/strong><\/p>\n\n\n\n\n\n\n\n
N\u00e1zev projektu<\/td>\nRoz\u0161\u00ed\u0159en\u00ed v\u00fdrobn\u00edho programu spole\u010dnosti VIDIA<\/td>\n<\/tr>\n
Program podpory OP PIK<\/td>\nInovace \u2013 III. V\u00fdzva \u2013 inova\u010dn\u00ed projekt<\/td>\n<\/tr>\n
Obdob\u00ed realizace projektu<\/td>\n7. 2. 2017 \u2013 21. 4. 2020<\/td>\n<\/tr>\n
Celkov\u00e9 zp\u016fsobil\u00e9 v\u00fddaje<\/td>\n10\u00a0450\u00a0520,49 K\u010d<\/td>\n<\/tr>\n
Dotace<\/td>\n4\u00a0702\u00a0734,20 K\u010d<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Firma \u010derpala finan\u010dn\u00ed podporu z programu Inovace v OP PIK<\/p>\n","protected":false},"author":1,"featured_media":26006,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[12,1],"tags":[],"class_list":["post-26004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clanky","category-novinky"],"publishpress_future_action":{"enabled":false,"date":"2026-05-06 18:58:05","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/posts\/26004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/comments?post=26004"}],"version-history":[{"count":0,"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/posts\/26004\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/media\/26006"}],"wp:attachment":[{"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/media?parent=26004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/categories?post=26004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/apiagentura.gov.cz\/cs\/wp-json\/wp\/v2\/tags?post=26004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}